Brief: Biohaven Presents Oncology Program Updates And Preliminary Clinical Data
28/05/2025 12:39
May 28 (Reuters) - Biohaven Ltd BHVN.N: BIOHAVEN PRESENTS ONCOLOGY PROGRAM UPDATES AND PRELIMINARY CLINICAL DATA SHOWCASING INNOVATIVE TROP2 AND FGFR3 ANTIBODY DRUG CONJUGATES (ADCS) INCORPORATING NOVEL TOPOIX PAYLOAD WITH POTENTIAL TO TREAT A WIDE VARIETY OF TUMORS Source text: ID:nPn2wsJXHa Further company coverage: BHVN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean